Navigation Links
Amylin Announces Preliminary Results of Annual Meeting of Stockholders
Date:5/27/2009

SAN DIEGO, May 27 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that, based on a preliminary vote count provided by its proxy solicitor, shareholders voted to elect at least 10 of the Company's nominees, including its two new independent nominees, Paul N. Clark and Paulo F. Costa, to Amylin's Board of Directors at the Company's Annual Meeting of Stockholders held today. The Company believes that no more than two of the five dissident nominees (one independent nominee from Eastbourne Capital Management, L.L.C. and one nominee from Carl Icahn) have been elected to Amylin's Board. Additionally, Mr. Icahn's proposal to reincorporate the Company from Delaware to North Dakota has been defeated.

The Company issued the following statement:

We appreciate the consideration and support of our shareholders, as well as the valuable insights offered to our Board and management team over the past several months. Today's outcome affirms that shareholders have confidence in the Company's plan to build value in 2009 and beyond, having apparently elected only two of the five dissident nominees.

We remain deeply committed to building long-term value for all of our shareholders, especially through the anticipated launch of exenatide once weekly, our investigational therapy that has the potential to significantly advance the treatment of type 2 diabetes. We thank all of our Directors for their tremendous commitment and contributions to Amylin. Our Board and management team will work with the new Directors to continue to bring transformational medicines to patients and maximize shareholder value.

IVS Associates, Inc., the independent Inspector of Elections, has indicated that it expects to issue a preliminary tabulation of the vote results early next week. Final results of the Annual Meeting will be announced once they are certified by the Inspector following the customary review and challenge period.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

Forward Looking Statements

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA, SYMLIN or exenatide once weekly may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results or achieve desired end-points; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates or sNDAs for label expansion requests, such as the exenatide once weekly NDA mentioned in this press release, may not be submitted timely or receive FDA approval; risks that our expense reductions will not be as large as we expect; risks that the restructured operations for exenatide will not produce the results we expect; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA, SYMLIN or exenatide once weekly. These and additional risks and uncertainties are described more fully in the Company's most recently filed Form 10-K and Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.

    CONTACTS:

    Alice Izzo
    Executive Director, Corporate Affairs
    Amylin Pharmaceuticals, Inc.
    (858) 642-7272
    alice.izzo@amylin.com

    or

    Steve Frankel / Averell Withers
    Joele Frank, Wilkinson Brimmer Katcher
    (212) 355-4449


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Amylin Pharmaceuticals Reports First Quarter Financial Results
8. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
9. Lilly and Amylin Set Date and Time for Conference Call
10. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
11. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... September 26, 2017 , ... Atmosera , a ... Management as a Service (RMaaS) to automate the deployment of websites and ... companies, e-tailers, and web development agencies who want to improve time-to-revenue with a ...
(Date:9/26/2017)... ... September 26, 2017 , ... CGL Electronic Security Inc., ... under its new umbrella, CGL Technologies, LLC. , The new CGL Technologies, LLC office ... Patitucci and Jon McCormack, both of whom have creative business development methods, who are ...
(Date:9/26/2017)... ... 26, 2017 , ... Two innovative companies are bringing to ... it is scientifically proven as well: ABAlife™. Euromed SA, a leading manufacturer of ... agreement with BioTherapeutics Inc. for patented technology for absiscic acid (ABA). , ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... As the ... news site, https://dealfeed.sutlr.com . People are constantly trying to find tips and stories ... industry, Sutlr deal feed brings you the top trending deals. The deals are organized ...
(Date:9/26/2017)... N.J. (PRWEB) , ... September 26, 2017 , ... ... at the shore, the John R. Elliott HERO Campaign for Designated Drivers proudly ... & Golf Club. , Thirty-one local bars and restaurants took on the challenge ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: